Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a <i>post-hoc</i> analysis of a randomised phase III study.

Li, Jing; Wang, Changzheng; Liu, Chuntao; Kang, Jian; Kong, Lingfei; Huang, Yijiang; Liu, Shuang; Huang, Mao; Wang, Lu; Fogel, Robert; Jaumont, Xavier; Yang, Jing; Zhong, Nanshan

Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study.

Li, Jing; Wang, Changzheng; Liu, Chuntao; Kang, Jian; Kong, Lingfei; Huang, Yijiang; Liu, Shuang; Huang, Mao; Wang, Lu; Fogel, Robert; Jaumont, Xavier; Yang, Jing; Zhong, Nanshan.

Afiliação

Li J; Allergy and Clinical Immunology Department, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Wang C; Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Liu C; Department of Respiratory Disease, West China Hospital, Sichuan University, Sichuan, China.
Kang J; Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China.
Kong L; Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China.
Huang Y; Department of Respiratory Disease, Hainan General Hospital, Hainan Clinical Medicine Research Institution, Hainan, China.
Liu S; Department of Respiratory Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Huang M; Department of Respiratory Disease, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Wang L; Beijing Novartis Pharma Co. Ltd., Beijing, China.
Fogel R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Jaumont X; Novartis Pharma AG, Basel, Switzerland.
Yang J; Beijing Novartis Pharma Co. Ltd., Beijing, China.
Zhong N; Allergy and Clinical Immunology Department, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

World Allergy Organ J ; 13(12): 100469, 2020 Dec.

Article em En | MEDLINE | ID: mdl-34611470

Palavras-chave

ACQ, Asthma Control Questionnaire; ANCOVA, Analysis of covariance; AQLQ, Asthma Quality of Life Questionnaire; Allergic; Asthma; CMH, Cochran-Mantel-Haenszel; China; EOS, Eosinophil; Eosinophils; FAS, Full analysis set; FCÎµR1, High affinity IgE binding receptor 1; FEV1, Forced expiratory volume in 1 s; GETE, Global Evaluation of Treatment Effectiveness; ICS, Inhaled corticosteroid; IL-5, Interleukin-5; IgE, Immunoglobulin-E; Immunoglobulin E; LABA, Long-acting ß agonist; LSM, Least squares mean; LSM-TD, Least squares mean treatment differences; OMA, Omalizumab; Omalizumab; PAR, Perennial allergic rhinitis; PBO, Placebo; PD, Pharmacodynamics; PEF, Peak expiratory flow; PK, Pharmacokinetic; QoL, Quality of life; RAST, Radio-allergosorbent test; RMU, Rescue medication use; SAR, Seasonal allergic rhinitis; ULOQ, Upper limit of quantification

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google